One of the goals of a digital diabetes management system is to improve patient’s self-management and control of their condition. High blood glucose level is defined as 180-400 mg/dL while severe hyperglycemia (above 400 mg/dL) is considered a medical emergency. Digital engagement can play a pivotal role in the care of patients with diabetes and other chronical conditions, assisting patients to enhance their compliance. The DarioTM Blood Glucose Monitoring System (BGMS) connects physically to a smart mobile device and automatically logs blood glucose measurements into designated App. Data is transmitted to the Dario cloud.

Method: A retrospective data evaluation study was performed on the DarioTM cloud database. A population of active type 2 diabetic (T2D) users that continuously measured their blood glucose using DarioTM BGMS during the full year of 2017 was evaluated. The study assessed the ratio of high (180-400 mg/dL) and hyperglycemic (>400mg/dL) blood glucose readings during full year of 2017 as recorded in the database. The average of high and hyperglycemic glucose readings were calculated in periods of 30-60, 60-90, 90-120, 120-150, 150-180, 180-210, 210-240, 240-270, 270-300, 300-330, 330-360 days and compared to first 30 days as a starting point of analysis.

Results: For 225 T2D active users the ratio of high events (180-400 mg/dL) was reduced gradually in 19.6% (from 23.4% to 18.8% of the entire measurements) from baseline compared to the 12th month of the year. Moreover, the ratio of severe hyperglycemia events (>400 mg/dL) was decreased in 57.8% (from 0.90% to 0.38% of the entire measurements) at the same period.

Conclusion: By means of glucose meter and App patients have the potential to promote behavioral modification and enhance adherence to diabetes management, demonstrating better glycemic control.

Disclosure

Y. Hershcovitz: Employee; Self; DarioHealth. S. Dar: Employee; Self; DarioHealth. E. Feniger: Employee; Self; DarioHealth.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.